Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support

Stephen Opat, EA Hawkes published in the Journal of Clinical Oncology.

Read article here.